Related Experiment Video

Updated: Aug 15, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

HIN-1, an inhibitor of cell growth, invasion, and AKT activation

Ian Krop1, Michele Taylor Parker, Noga Bloushtain-Qimron

  • 1Department of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Cancer Research
|November 4, 2005
PubMed

Insights

The HIN-1 gene, silenced in many cancers, inhibits tumor growth, migration, and invasion. Its tumor suppressor function appears linked to inhibiting the AKT signaling pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The HIN-1 gene, encoding a secreted protein, is frequently silenced by methylation in various carcinomas (breast, prostate, lung, pancreatic).
  • This silencing suggests HIN-1 may function as a tumor suppressor.
  • HIN-1 exhibits high-affinity binding to epithelial cell surfaces, though its receptor remains unidentified.

Purpose of the Study:

  • To investigate the functional role of HIN-1 in cancer.
  • To elucidate the molecular mechanisms underlying HIN-1's potential tumor suppressor activities.
  • To determine the signaling pathways affected by HIN-1 expression.

Main Methods:

  • Assessing HIN-1's effects on anchorage-dependent and independent cell growth, migration, and invasion.
  • Analyzing cell cycle progression and retinoblastoma protein (Rb) phosphorylation in synchronized and exponentially growing cells expressing HIN-1.
  • Investigating the impact of HIN-1 on key signaling pathways, including AKT phosphorylation and activation.
  • Evaluating the effect of constitutively active AKT on HIN-1-mediated growth arrest.

Main Results:

  • HIN-1 significantly inhibits cell growth, migration, and invasion.
  • In synchronized cells, HIN-1 suppresses cell cycle reentry and Rb phosphorylation.
  • In exponentially growing cells, HIN-1 induces apoptosis without cell cycle arrest.
  • HIN-1 expression inhibits mitogen-induced AKT phosphorylation and activation.
  • Overexpression of constitutively active AKT rescues HIN-1-induced growth arrest.

Conclusions:

  • HIN-1 demonstrates potent tumor suppressor functions.
  • HIN-1's tumor suppressor activities are mediated, at least in part, through the inhibition of the AKT signaling pathway.
  • These findings support the therapeutic potential of targeting HIN-1 in cancer treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...